Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation

Published:2021-11 Issue:12 Volume:73 Page:2271-2281
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Shi Zhenrui¹^ORCID,Garcia‐Melchor Emma²,Wu Xuesong³,Getschman Anthony E.⁴^ORCID,Nguyen Mimi³,Rowland Douglas J.³,Wilson Machelle³,Sunzini Flavia²,Akbar Moeed²,Huynh Mindy³,Law Timothy³^ORCID,Raychaudhuri Smriti K.⁵,Raychaudhuri Siba P.⁵,Volkman Brian F.⁴,Millar Neal L.²^ORCID,Hwang Sam T.³

Affiliation:

1. University of California, Davis, Sacramento, and Sun Yat‐sen Memorial Hospital and Sun Yat‐sen University Guangzhou China

2. University of Glasgow Glasgow UK

3. University of California Davis, Sacramento

4. Medical College of Wisconsin Milwaukee

5. University of California Davis

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Psoriasis Foundation

Small Business Innovation Research

Pfizer

Medical Research Council

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41882

Reference46 articles.

1. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

2. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

4. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

5. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: Evaluation for preventive, therapeutic, and Recurrent management of psoriasis;Bioactive Materials;2024-11

2. Association Between Serum Chemokine Ligand 20 Levels and Disease Activity and Th1/Th2/Th17-Related Cytokine Levels in Rheumatoid Arthritis;Journal of Interferon & Cytokine Research;2023-11-01

3. Cellular characterisation of advanced osteoarthritis knee synovium;Arthritis Research & Therapy;2023-08-23

4. CCL20 inhibition for treating inflammation in ankylosing spondylitis;Rheumatology;2023-06-05

5. A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6⁺T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation;Journal of Pharmacology and Experimental Therapeutics;2023-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3